Submitted:
19 April 2024
Posted:
23 April 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
3. Results
3.1. Effects of the Mediterranean Diet on the Intestinal Microbiome, Obesity, and Metabolic Syndrome
3.2. Effects of Probiotics on the Intestinal Microbiome, Obesity and Metabolic Syndrome
3.3. Effects of Prebiotics on the Intestinal Microbiome Obesity and Metabolic Syndrome
3.4. Effects of Phytochemicals on the Intestinal Microbiome, Obesity and Metabolic Syndrome
4. Discussion
5. Conclusions
Funding
Data Availability Statement
Conflicts of Interest
References
- Srivastava A, Prabhakar M R, Mohanty A, Meena S S. Influence of gut microbiome on the human physiology. Systems Microbiology and Biomanufacturing 2022, 2:217–231. [CrossRef]
- Croci S, D’Apolito L I, Gasperi V, Catani M V, Savini I, Dietary Strategies for Management of Metabolic Syndrome: Role of Gut Microbiota Metabolites, Nutrients 2021, 13, 138. [CrossRef]
- Mazidi M, Rezaie P, Kengne AP, Mobarhan MG, Ferns G, Gut microbiome and metabolic syndrome, Diabetes & Metabolic Syndrome: Clinical Research & Reviews 10S (2016) S150–S157.
- Beam A, Clinger E, Hao L, Effect of Diet and Dietary Components on the Composition of the Gut Microbiota, Nutrients 2021, 13, 2795. [CrossRef]
- Montero CG, Martínez OF, Gómez-Lahoz AM, Pekarek L, Castellanos AJ, Noguerales-Fraguas F, Coca S, Guijarro L, García-Honduvilla N, Asúnsolo A, Sanchez-Trujillo L, Lahera G, Bujan J, Monserrat J, Álvarez-Mon M, Álvarez-Mon MA, Ortega MA, Nutritional Components in Western Diet Versus Mediterranean Diet at the Gut Microbiota–Immune System Interplay. Implications for Health and Disease, Nutrients 2021, 13, 699. [CrossRef]
- Wang B, Yao M, Lv L, Ling Z, Li L, The Human Microbiota in Health and Disease, Engineering 3 (2017) 71–82. [CrossRef]
- Conlon M, Bird A, The Impact of Diet and Lifestyle on Gut Microbiota and Human Health, Nutrients 2015, 7, 17–44. [CrossRef]
- Magne F, Gotteland M, Gauthier L, Zazueta A, Pesoa S, Navarrete P, Balamurugan R, The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients? Nutrients 2020, 12, 1474.
- Siqueira J S, Palacio T L N, Vieira TA, Nakandakare-Maia ET, Grandini N A, Togneri Ferron A J, Francisqueti-Ferron FV, Correa CR. An overview of the complex interaction between obesity and target organ dysfunction: Focus on redox-inflammatory state. Nutrire 2023, 48:21. [CrossRef]
- Cerdó T, García-Santos JA, Bermúdez MG, Campoy C, The Role of Probiotics and Prebiotics in the Prevention and Treatment of Obesity, Nutrients 2019, 11, 635. [CrossRef]
- Laparra JM, Sanz Y, Interactions of gut microbiota with functional food components and nutraceuticals, Pharmacological Research 61 (2010) 219–225.
- Dzah CM, Asante-Donyina D, Letsyo E, Dzikunoo J, Suglo Adams Z, Dietary Polyphenols and Obesity: A Review of Polyphenol Effects on Lipid and Glucose Metabolism, Mitochondrial Homeostasis, and Starch Digestibility and Absorption, Plant Foods for Human Nutrition (2023) 78:1–12. [CrossRef]
- Kawadaa T, Food-derived regulatory factors against obesity and metabolic syndrome, Bioscience, Biotechnology, and Biochemistry, 2018 Vol. 82, no. 4, 547–553.
- Li HY, Zhou DD, Gan RY, Huang SY, Zhao CN, Shang A, Xiao-Yu Xu XY, Li HB, Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review, Nutrients 2021, 13, 3211. [CrossRef]
- O’Connora S, Chouinard-Castonguaya S, Gagnona C, Iwona Rudkowskaa I, Prebiotics in the management of components of the metabolic syndrome, Maturitas 104 (2017) 11–18.
- Green M, Arora K, Prakash S, Microbial Medicine: Prebiotic and Probiotic Functional Foods to Target Obesity and Metabolic Syndrome, Int. J. Mol. Sci. 2020, 21, 2890. [CrossRef]
- Ferrarese R, Ceresola ER, Preti A, Canducci F, Probiotics, prebiotics and synbiotics for weight loss and metabolic syndrome in the microbiome era, European Review for Medical and Pharmacological Sciences 2018; 22: 7588-7605.
- Wang PX, Deng XR, Zhang CH, Yuan HJ, Gut microbiota and metabolic syndrome, Chinese Medical Journal 2020;133(7). [CrossRef]
- Las Heras V, Melgar S, Mac Sharry J, Gahan C, The Influence of the Western Diet on Microbiota and Gastrointestinal Immunity, Annu. Rev. Food Sci. Technol. 2022. 13:489–512. [CrossRef]
- Peng M, Tabashsum Z, Anderson M, Truong A, Houser A, Padilla J, Akmel A, Bhatti J, Rahaman S, Biswas D, Effectiveness of probiotics, prebiotics, and prebiotic-like components in common functional foods Compr Rev Food Sci Food Saf. 2020; 19:1908–1933.
- Choque Delgado GT, da Silva Cunha Tamashiro WM, Role of prebiotics in regulation of microbiota and prevention of obesity, Food Research International 113 (2018) 183-188.
- Luisi M, Lucarini L, Biffi B, Rafanelli E, Pietramellara G, Durante M, Vidali S, Provensi G, Madiai S, Francesca Gheri C, Masini E, Ceccherini M T, Effect of Mediterranean Diet Enriched in High Quality Extra Virgin Olive Oil on Oxidative Stress, Inflammation and Gut Microbiota in Obese and Normal Weight Adult Subjects, Front. Pharmacol. (2019) 10:1366. [CrossRef]
- Meslier V, Laiola M, Munch H, De Filippis F, Roume H, Quinquis B, Giacco R, Mennella I, Ferracane R, Pons N, Pasolli E, Rivellese A, Ove Dragsted L, Vitaglione P, Dusko Ehrlich S, Ercolini D, Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake, Gut 2020;69:1258–1268. [CrossRef]
- Ismael S, Marta P. Silvestre M, Vasques M, Araújo J, Morais J, Duarte M I, Pestana D, Faria A, Pereira-Leal J, Vaz J, Ribeiro P, Teixeira D, Cláudia Marques C, Calhau C, A Pilot Study on the Metabolic Impact of Mediterranean Diet in Type 2 Diabetes: Is Gut Microbiota the Key?, Nutrients 2021, 13, 1228. [CrossRef]
- Gutiérrez-Díaz I, Fernández-Navarro T, Sánchez B, Margollesb A, González S, Mediterranean diet and faecal microbiota: A transversal study, Food Funct., 2016, 7, 2347–2356. [CrossRef]
- Othman R, Amor N, Mahjoub F, Berriche O, Ghali C, Gamoudi A, Jamoussi H, A clinical trial about effects of prebiotic and probiotic supplementation on weight loss, psychological profile and metabolic parameters in obese subjects, Endocrinol Diab Metab. 2023;6:e402.
- Sharafedtinov K, Plotnikova O, Alexeeva R, Sentsova T, Songisepp E, Stsepetova J, Smidt I, Mikelsaar M, Hypocaloric diet supplemented with probiotic cheese improves body mass index and blood pressure indices of obese hypertensive patients – a randomized double-blind placebo-controlled pilot study, Nutrition Journal 2013, 12:138. [CrossRef]
- Bernini L, Colado Sim~ao A, Alfieri D, Batisti Lozovoy M, Lourenco Mari N, Batista de Souza C, Dichi I, Nobre Costa G, Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome, Nutrition 32 (2016) 716–719. [CrossRef]
- Rezazadeh L, Pourghassem Gargari B, Asghari Jafarabadi M, Alipour B, Effects of probiotic yogurt on glycemic indexes and endothelial dysfunction markers in patients with metabolic syndrome, Nutrition 62 (2019) 162-168. [CrossRef]
- Szuli´nska M, Łoniewski I, van Hemert S, Sobieska M, Bogda´nski P, Dose-Dependent Effects of Multispecies Probiotic Supplementation on the Lipopolysaccharide (LPS) Level and Cardiometabolic Profile in Obese Postmenopausal Women: A 12-Week Randomized Clinical Trial, Nutrients 2018, 10, 773. [CrossRef]
- Parnell J, Klancic T, Reimer R, Oligofructose Decreases Serum Lipopolysaccharide and Plasminogen Activator Inhibitor-1 in Adults with Overweight/Obesity, Obesity (2017) 25, 510-513. [CrossRef]
- Dehghan P, Pourghassem Gargari B, Jafar-Abadi M A, Aliasgharzadeh A, Inulin controls inflammation and metabolic endotoxemia in women with type 2 diabetes mellitus: A randomized-controlled clinical trial, Int J Food Sci Nutr, 2014; 65(1): 117–123. [CrossRef]
- Birkeland E, Gharagozlian S, Birkeland K, Valeur J, Måge I, Rud I, Aas A M, Correction to: Prebiotic efect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: A randomised controlled trial European Journal of Nutrition (2020) 59:3339–3340.
- Nicolucci A, Hume M, Martínez I, Mayengbam S, Walter J, Reimer R, Prebiotics Reduce Body Fat and Alter Intestinal Microbiota in Children Who Are Overweight or With Obesity, Gastroenterology 2017;153:711–722. [CrossRef]
- Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour-Mobarhan M, Ferns G, Effects of Supplementation with Curcuminoids on Dyslipidemia in Obese Patients: A Randomized Crossover Trial. Phytother. Res. 27: 374–379 (2013). [CrossRef]
- Rehman A, Tyree S, Fehlbaum S, DunnGalvin G, Panagos C, Guy B, Patel S, Dinan T, Duttaroy A, Duss R, Steinert R, A water-soluble tomato extract rich in secondary plant metabolites lowers trimethylamine-n-oxide and modulates gut microbiota: A randomized, double-blind, placebo-controlled cross-over study in overweight and obese adults, The Journal of Nutrition 153 (2023) 96-105. [CrossRef]
- Walker J, Eckardt P, Aleman J, Correa da Rosa J, Liang Y, Iizumi T, Etheve S, Blaser M, Breslow J, Holt P, The effects of trans-resveratrol on insulin resistance, inflammation, and microbiota in men with the metabolic syndrome: A pilot randomized, placebo-controlled clinical trial, Journal of Clinical and Translational Research 2018; 4(2): 122-135.
- Korsholm A S, Nordstrøm Kjær T, Ornstrup M J, Bønløkke Pedersen S, Comprehensive Metabolomic Analysis in Blood, Urine, Fat, and Muscle in Men with Metabolic Syndrome: A Randomized, Placebo-Controlled Clinical Trial on the Effects of Resveratrol after Four Months’ Treatment. Int. J. Mol. Sci. 2017, 18, 554. [CrossRef]
- de la Torre R, Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation A randomized controlled trial, Eur J Nutr (2004) 43:140–147.
- Sarapis K, George E, Marx W, Mayr H, Willcox J, Esmaili T, Powell K, Folasire O, Lohning A, Garg M, Thomas C, Itsiopoulos C, Moschonis G, Extra virgin olive oil high in polyphenols improves antioxidant status in adults: A double-blind, randomized, controlled, cross-over study (OLIVAUS), Eur J Nutr (2022) 61:1073–1086.
- Hul MV, Cani PD, Targeting Carbohydrates and Polyphenols for a Healthy Microbiome and Healthy Weight, Current Nutrition Reports (2019) 8:307–316.
- Merra G, Noce A, Marrone G, Cintoni M, Tarsitano MG, Capacci A, De Lorenzo A Influence of Mediterranean Diet on Human Gut Microbiota. Nutrients 2021, 13, 7.
- Song X, Wang L, Liu Y, Zhang X, Weng P, Liu L, Zhang R, Wu Z, The gut microbiota–brain axis: Role of the gut microbial metabolites of dietary food in obesity, Food Research International 153 (2022) 110971. [CrossRef]
- Deledda A, Annunziata G, Tenore GC, Palmas V, Manzin A, Velluzzi F, Diet-Derived Antioxidants and Their Role in Inflammation, Obesity and Gut Microbiota Modulation, Antioxidants 2021, 10, 708. [CrossRef]
- Dayi T, Ozgoren M, Effects of the Mediterranean diet on the components of metabolic syndrome. J Prev Med Hyg 2022, 63 (SUPPL. 3): E56-E64. [CrossRef]
| Study Type | Study sample/Duration | Participants | Protocol | Summary of Results | Study Reference |
|---|---|---|---|---|---|
| Clinical trial | 36 participants / 3 months | 18 overweight/ obese subjects, 18 normal weight controls | Participants followed Mediterranean diet enriched with 40g/day HQ-EVOO | Mediterranean diet rich in HQ-EVOO leads to an increasementof Lactobacillus strains in Gut Microbiota | [22] |
| Randomized controlled trial | 82 Subjects/8 weeks | 82 overweight and obese Subjects | 43 participants consumed a Mediterranean diet and 39 maintained their regular diets | Reductions of carnitine and plasma cholesterol and increased levels of Faecalibacterium prausnitzii and insulin sensitivity | [23] |
| 12-week single-arm pilot trial | 9 participants/12 weeks | Men-women 40-80y, non smokers, with diagnosis of type 2 diabetes | Participants followed nutritional counseling sessions according to Mediterranean Diet | Increase of microbiota variety, Prevotella/ Bacteroides ratio increasement and reduction of HbA1c | [24] |
| Transversal study | 31 participants | 31 adults, 23 women, 8 men, 42y with non-declared pathology | Consumption of Mediterranean diet | Mediterranean diet increased the population of Bacteroidetes, Prevotella and decreased the population of Firmicutes and Lachnospiraceae | [25] |
| Study Type | Study sample/Duration | Participants | Protocol | Summary of Results | Study Reference |
|---|---|---|---|---|---|
| Prospective interventional study | 45 obese patients/1 month | 42 women, 3men /33-63 y. | Division of patients into three groups: low- calorie diet alone, prebiotic supplementation, probiotic supplementation | Prebiotic and probiotic groups significantly decreased fat mass, improvement of insulinemia in the prebiotic group compared to the diet- alone group and the probiotic group showed an improvement in fasting blood glucose compared to the diet group. | [26] |
| Randomized, double-blind, placebo-controlled, parallel pilot study | 40 patients/3 weeks | 30–69 years/ with Mets, obesity and arterial hypertonia (>130/85 mm Hg) | 25 subjects ingested probiotic cheese and 15 ingested control cheese | Τhe hypocaloric diet with the addition of a probiotic cheese reduced arterial BP, BMI and the risk of Mets in obese patients with hypertension. |
[27] |
| A randomized trial. | 51 patients with MetS/45 days | 18- 60 years | Control group or untreated patients(n25) and a probiotic group (n26). The probiotic groups were required to consume 80 mL of probiotic milk containing B. lactis ssp. | B. lactis significantly ameliorated lipid profile, BMI and cytokine levels in patients with MetS. | [28] |
| A randomized, double-blind, placebo-controlled clinical trial | 44 patients/8 weeks | 22 men and 22 women with MetS. 20 to 65 years old. | Participants were randomly divided into two groups a treatment or control group and consumed 300 g/d of probiotic yogurt containing Bifidobacterium lactis and Lactobacillus acidophilus or a regular yogurt for 8 weeks respectively. | Consumption of probiotic yogurt ameliorated fasting blood glucose and improved endothelial function markers. | [29] |
| A randomized, placebo-controlled, double-blind intervention | 81 participants/12-week | 81 obese postmenopausal women | Division into three groups that received a placebo, a low dose, or a high dose of lyophilizate powder containing live multispecies probiotic bacteria. | Τhere was an improvement of waist circumference, lipid profile, visceral fat, glucose metabolism, and LPS concentration in obese postmenopausal women | [30] |
| Study Type | Study sample/Duration | Partecipants | Protocol | Summary of Results | Study Reference |
|---|---|---|---|---|---|
| A randomized, double-blind, placebo-controlled trial | 37 participants /12 weeks | Adults with overweight and obesity. | 21 g of oligofructose or a maltodextrin placebo | 40% reduction of LPS concentrations in the oligofructose group compared to a 48% increasement in the placebo group. PAI-1 reduced to a greater extent in the oligofructose group. |
[31] |
| Triple-blind randomized controlled study | 54 patients/8 weeks | diabetic females aged 20–65 years. | The intervention group consumed 10 g/d inulin supplement and the control group consumed similar amounts of maltodextrin |
Inulin supplementation modulates metabolic endotoxemia and inflammation in women with type 2. | [32] |
| A placebo-controlled crossover study | 25 patients (15 men) /6 weeks | Adult men and women with type 2 diabetes /41–71 y. | Consumption of 16 g of inulin-type fructans (a mixture of oligofructose and inulin) and 16 g placebo (maltodextrin) in a randomized order |
Inulin-type fructans leads to moderate improvement of gut microbiota composition | [33] |
| Single-center, double-blind placebo-controlled trial | 38 children /16 weeks |
Male and female children, 20 in the prebiotic group and 18 in the control Group, aged 7–12 years with overweight or obesity | Supplementation of either oligofructose-enriched inulin 8 g/day or maltodextrin placebo once daily for 16 weeks |
Consumption of Prebiotics normalized weight gain, ameliorated percent body fat and significantly modified gut microbial Composition enriching concentrations of Bifidobacterium spp. |
[34] |
| Study Type | Study sample/Duration | Participants | Protocol | Summary of Results | Study Reference |
|---|---|---|---|---|---|
| Randomized, double-blind, placebo-controlled, crossover trial. |
30 Participants /30 days |
18–65 y | Curcuminoids (1 g/day), or placebo. | Curcuminoid supplementation (1 g/day for 30 days) reduced triglycerides concentrations in serum |
[35] |
| A double-blind, placebo-controlled, cross-over study | 22 participants /4 weeks |
Overweight and obese adults. | 2150 mg of a water-soluble tomato extract rich in polyphenols per day or placebo (maltodextrin) for 4 weeks with a 6-week wash-out between interventions. | Significantly reduced urine TMAO, related with changes in microbial composition. | [36] |
| A double-blind pilot randomized parallel group design placebo-controlled study |
28 participants/35-days | Obese men with MetS | Resveratrol 1 g orally twice daily or placebo while consuming a western-style diet |
Improvement in insulin sensitivity and glucose tolerance |
[37] |
| A randomized, placebo-controlled, double-blinded, single-center study. | 66 participants/ 4 months | Male gender,30- 60 y, and MetS. |
Randomized to either resveratrol or placebo treatment | Urinary derivatives of amino acids, which reflect the synthesis of the gut microbiota, were altered after resveratrol treatment. |
[38] |
| Double blind, cross-over, randomized, clinical trial |
30 healthy non-smoking volunteers/ 3 weeks |
Adults/both male and female | Common, virgin, and refined olive oils were sequentially consumed over three periods of 3 weeks |
Reduction in vivo of LDL oxidation and increasement of T and HT in urine | [39] |
| Double-blind cross-over trial | 43 participants/3 weeks | 20 -70 y, 66% females,44% of study participants were overweight and 4% were obese | 60 mL/day of HPOO (320 mg/kg polyphenols) or LPOO (86 mg/kg polyphenols) for three weeks. | Significant reduction of ox-LDL and CRP in plasma and increase in the TAC of the plasma | [40] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).